Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 6/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786110 | 0.87 | ATR (0.37) | CYP4F2CYP4A11ATRRETDGAT2 | |
| SCHEMBL23791913 | 0.87 | ATR (0.43) | ATR | |
| SCHEMBL20765180 | 0.83 | GAA (0.36) | CYP4F2CYP4A11ATRRETDGAT2 | |
| SCHEMBL31089969 | 0.83 | GAA (0.36) | CYP4F2CYP4A11ATRRETDGAT2 | |
| SCHEMBL20786492 | 0.82 | CYP4F2 (0.36) | MAPK1CYP4F2CYP4A11ATRRET | |
| SCHEMBL20764887 | 0.82 | CYP4F2 (0.39) | MAPK1CYP4F2CYP4A11ATRRET | |
| SCHEMBL20786559 | 0.82 | CYP4F2 (0.39) | CYP4F2CYP4A11ATRRETDGAT2 | |
| SCHEMBL29989125 | 0.81 | CYP4F2 (0.41) | MAPK1CYP4F2CYP4A11ATRRET | |
| SCHEMBL29168077 | 0.80 | IDO1 (0.35) | CYP4F2CYP4A11RETDGAT2 | |
| SCHEMBL23792790 | 0.79 | CYP4F2 (0.34) | CYP4F2CYP4A11ATRDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111032656-A | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019037640-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K20, MAP3K19, MAP3K1 | MAPK1 40/4885CYP4F2 1915/4885CYP4A11 1071/4885 |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K20, MAP3K19, MAP3K1 | MAPK1 40/4885CYP4F2 1915/4885CYP4A11 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.